Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Placebo to match BI 730357
Drug: Ciprofloxacin

First Posted Date: 2019-11-01

Last Posted Date: 2023-07-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT04147260

Locations: 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 1387446
Drug: BI 754091

First Posted Date: 2019-11-01

Last Posted Date: 2024-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT04147234

Locations: 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇪🇸
CIO Clara Campal, Madrid, Spain

and more 4 locations

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 905681

First Posted Date: 2019-11-01

Last Posted Date: 2023-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21

Registration Number: NCT04147247

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

Phase 1

Completed

Conditions: Neoplasm

Interventions: Drug: BI 891065

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT04138823

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

Completed

Conditions: COPD

Interventions: Drug: LABA/ICS
Drug: Tiotropium bromide + Olodaterol

First Posted Date: 2019-10-24

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42953

Registration Number: NCT04138758

Locations: 🇺🇸
HealthCore, Inc., Watertown, Massachusetts, United States

A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

Phase 1

Completed

Conditions: Gastrointestinal Neoplasms
Cholangiocarcinoma
Pancreatic Neoplasms

Interventions: Drug: BI 905711

First Posted Date: 2019-10-24

Last Posted Date: 2025-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 110

Registration Number: NCT04137289

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

and more 15 locations

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Phase 1

Active, not recruiting

Conditions: Solid Tumors, KRAS Mutation; SOS1

Interventions: Drug: BI 1701963
Drug: Trametinib

First Posted Date: 2019-10-01

Last Posted Date: 2025-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 71

Registration Number: NCT04111458

Locations: 🇺🇸
Sarah Cannon Research Institute-Nashville-48456, Nashville, Tennessee, United States
🇳🇱
Erasmus Medisch Centrum-ROTTERDAM-50697, Rotterdam, Netherlands
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495
Drug: Placebo
Drug: Midazolam

First Posted Date: 2019-09-27

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 87

Registration Number: NCT04107805

Locations: 🇩🇪
Fraunhofer ITEM, Hannover, Germany

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 764198
Drug: Matching placebo

First Posted Date: 2019-09-25

Last Posted Date: 2020-11-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 52

Registration Number: NCT04102462

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin

First Posted Date: 2019-09-23

Last Posted Date: 2021-03-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9571

Registration Number: NCT04098575

Locations: 🇩🇪
Diabetes Agenda 2010 GmbH, Mahlow, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy